Eyelash Poliosis -CEW

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== Eyelash Poliosis ======


====Causes====
  * Idiopathic- diagnosis of exclusion
  * Vitiligo
    * acquired pigmentary disorder of skin and hair with depigmented skin patches
    * frequently associated with other autoimmune conditions. 
  * Chronic blepharitis
  * Post-inflammatory change from atopic or contact dermatitis especially if there is a history of eczema or dermatitis involving the periocular region. 
  * Drug-induced 
    * topical prostaglandin F(2α) analogues used for glaucoma, usually reversible poliosis 
  * Skin lesions
    * Cutaneous/ocular malignant melanoma may rarely present with poliosis due to destruction of melanocytes adjacent to a melanoma; biopsy is required for diagnosis
    * Halo nevus or other benign nevus-associated poliosis 
      * localized whitening of lashes adjacent to a melanocytic nevus. 
  * Uveitis associated poliosis 
    * Phthisis bulbi
    * Vogt–Koyanagi–Harada (VKH) disease 
      * a multisystem autoimmune disorder 
      * bilateral granulomatous uveitis, auditory symptoms, and meningeal signs.
    * Sympathetic ophthalmia is a bilateral granulomatous uveitis

====Resources====
  - [[https://pubmed.ncbi.nlm.nih.gov/21839315|Vitiligo: A Comprehensive Overview Part I. Introduction, Epidemiology, Quality of Life, Diagnosis, Differential Diagnosis, Associations, Histopathology, Etiology, and Work-Up. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V.Journal of the American Academy of Dermatology. 2011;65(3):473-491.]]
  - [[https://www.nejm.org/doi/full/10.1056/NEJMra2023911|Atopic Dermatitis.Ständer S. The New England Journal of Medicine. 2021;384(12):1136-1143.]]
  - [[https://pubmed.ncbi.nlm.nih.gov/15126178/|Topical Prostaglandin F(2alpha) Analog Induced Poliosis. Chen CS, Wells J, Craig JE. American Journal of Ophthalmology. 2004;137(5):965-6.]]
  - [[https://pubmed.ncbi.nlm.nih.gov/23850259/|Poliosis Circumscripta: Overview and Underlying Causes. Sleiman R, Kurban M, Succaria F, Abbas O. Journal of the American Academy of Dermatology. 2013;69(4):625-33.]]
  - [[https://pubmed.ncbi.nlm.nih.gov/34145419/|Precise, Simplified Diagnostic Criteria and Optimised Management of Initial-Onset Vogt-Koyanagi-Harada Disease: An Updated Review. Herbort CP, Tugal-Tutkun I, Abu-El-Asrar A, et al. Eye (London, England). 2022;36(1):29-43.]]
  - [[https://pubmed.ncbi.nlm.nih.gov/34494974/|Recent Advances in Diagnosis and Management of Sympathetic Ophthalmia. Fromal OV, Swaminathan V, Soares RR, Ho AC. Current Opinion in Ophthalmology. 2021;32(6):555-560.]]
  - [[https://pubmed.ncbi.nlm.nih.gov/30392755/|Guidelines of Care for the Management of Primary Cutaneous Melanoma. Swetter SM, et al. Journal of the American Academy of Dermatology. 2019;80(1):208-250.]]

{{tag>ddx}}
ddx